![]() ![]() According to the National Center for Biotechnology Information (NCBI) data, the occurrence of bleeding for patients taking warfarin has been projected at 15-20% each year. The high risk of bleeding varies with the anticoagulant agent used. Report AttributesĮxpected Growth Rate of the North American Market (2022-2032)Īnticipated Growth Rate of the Asia Pacific Market (2022-2032)īleeding disorders can happen as a result of some medications, such as blood thinner, which includes warfarin, heparin, and aspirin. Furthermore, across the 2022-2032 period of assessment, growth is expected to accelerate at a whopping 15.0% CAGR, reaching US$ 4,601.22 Million. In FY 2022, the Anticoagulant Reversal Drugs market reached a valuation of US$ 989.0 Million and is likely to register a Y-o-Y growth rate of 13.0% in 2023, closing at US$ 1,137.35 Million. Anticoagulant Reversal Drugs Market outlook (2022-2032) ![]()
0 Comments
Leave a Reply. |